Cargando…
Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS)
The purpose of this study was to assess the efficacy and safety of the combination of tirofiban with intravenous thrombolysis (IVT) in treating patients with capsular warning syndrome (CWS) who failed to respond to the treatment of intravenous thrombolysis alone. Tirofiban was approved for the treat...
Autores principales: | Liu, Yunzhu, Li, Shiyong, Hao, Dongdong, Zhang, Zhongping, Yi, Yongxin, Fang, Jiayang, Lin, Weizhi, Zhang, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709144/ https://www.ncbi.nlm.nih.gov/pubmed/36466171 http://dx.doi.org/10.3389/fnins.2022.1026127 |
Ejemplares similares
-
Intravenous tirofiban therapy for patients with capsular warning syndrome
por: Li, Wei, et al.
Publicado: (2019) -
Correction: Intravenous tirofiban therapy for patients with capsular warning syndrome
Publicado: (2019) -
Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis
por: Zhang, Yan, et al.
Publicado: (2022) -
Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban
por: Seitz, Rüdiger J., et al.
Publicado: (2012) -
Safety and Efficacy of Tirofiban During Mechanical Thrombectomy for Stroke Patients with Preceding Intravenous Thrombolysis
por: Huo, Xiaochuan, et al.
Publicado: (2020)